Related Experiment Video
Updated: Jan 11, 2026

06:52
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.7K
Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis
Christopher M Henstridge1, Bradley T Hyman2, Tara L Spires-Jones3
1The University of Edinburgh Centre for Discovery Brain Sciences, UK Dementia Research Institute, Edinburgh, UK.
Nature Reviews. Neuroscience
|January 16, 2019
Summary
Alzheimer disease symptoms stem from neural circuit damage. Understanding the shifting interactions between brain cells like neurons and glia is key to developing new Alzheimer
Area of Science:
- Neuroscience
- Cellular Biology
- Pathology
Background:
- Alzheimer disease (AD) symptoms correlate with neural circuit dysfunction.
- Neurons operate within a complex cellular network, not in isolation.
- The brain's healthy function relies on balanced interactions among neurons, astrocytes, microglia, and vascular cells.
Purpose of the Study:
- To investigate the dynamic interplay of cellular interactions in Alzheimer disease.
- To understand how these interactions evolve throughout the disease progression.
- To identify potential therapeutic targets by moving beyond a solely neuronal focus.
Main Methods:
- This study reviews emerging evidence on cellular interactions in Alzheimer disease.
- Analysis focuses on the balance shifts between neurons, astrocytes, microglia, and vascular cells.
- The research examines how these interactions change from early to later stages of the disease.
Main Results:
- The balance of interactions between brain cells is perturbed in Alzheimer disease.
- Early cellular changes may initially protect neural circuits.
- Later, a failure to restore this balance leads to detrimental effects.
Conclusions:
- Alzheimer disease involves complex, dynamic cellular interactions, not just neuronal loss.
- Understanding the evolving roles of astrocytes, microglia, and vascular cells is crucial.
- Targeting these cellular interactions may offer novel therapeutic strategies for Alzheimer disease.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K

